RedHill Biopharma Ltd. (RDHL) shares are rising above 5% in pre-market today, after the company said it is actively pursuing an exploratory program intended to evaluate the activity of opaganib and RHB-107, individually and in combination with hydroxychloroquine and other compounds in the treatment of COVID-19.
from RTT - Before the Bell https://ift.tt/2VZgnl8
via IFTTT
No comments:
Post a Comment